Benefits seen in terms of pathologic complete response and event-free survival for resectable non-small cell lung cancer <\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, May 1, 2023 (HealthDay News) — For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant and adjuvant durvalumab offers benefits in terms of pathologic complete response and event-free survival (EFS), according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 14 to 19 in Orlando, Florida.<\/p>\n
John V. Heymach, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a randomized trial involving adults with treatment-naive resectable NSCLC (stage II to IIIB). Participants were randomly assigned to receive either neoadjuvant durvalumab or placebo and platinum-based chemotherapy before surgery (four cycles), followed by further durvalumab or placebo (up to 12 cycles). A total of 802 patients were randomly assigned; 799 received treatment (400 durvalumab; 399 placebo).<\/p>\n
The researchers found that the median event-free survival follow-up was 11.7 months. Patients in the durvalumab versus placebo arms had a significantly higher pathological complete response rate (17.2 versus 4.3 percent) and significantly prolonged EFS (median, not reached versus 25.9 months). During the overall treatment period, maximum grade 3\/4 any-cause adverse events occurred in 42.3 and 43.4 percent in the durvalumab and placebo groups, respectively.<\/p>\n
“This study shows that a combination of neoadjuvant and adjuvant durvalumab offers benefit for patients and may have the potential to change standard-of-care for patients with resectable non-small cell lung cancer,” Heymach said in a statement.<\/p>\n
Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, which manufactures durvalumab and conducted the study.<\/p>\n
Press Release<\/a><\/p>\n